Kriya Therapeutics

Vertically integrated AAV gene-therapy company for common chronic diseases. It owns its own 3,000L GMP plant and has raised roughly $0.9B privately.

1. Core Product / Service

Kriya was founded in 2019 and launched in 2020 with dual headquarters in Palo Alto and North Carolina's Research Triangle; it is now headquartered in Morrisville, NC [1][2]. It develops AAV gene therapies, and some of its programs use "gene-encoded biologics" in place of chronic injections. Its targets are large indications rather than rare diseases.

The company says it has five programs in the clinic. All are Phase 1/2 per ClinicalTrials.gov [2]:

Acquisitions: Warden Bio in January 2022 and Redpin Therapeutics in November 2022 [2].

2. Target Users & Pain Points

• Patients: people with chronic diseases that today need frequent injections, such as GA and TED. A single gene-therapy dose could replace repeat dosing.
• Pain addressed: manufacturing cost and scale have kept AAV confined to rare diseases. Kriya's argument is that owning large-scale manufacturing makes common indications economically viable.

3. Competitive Landscape

4. Unique Observations

• Wet lab and manufacturing are its strategy, not just a cost line.
  • 2020: secured a 51,350 sq ft manufacturing facility in RTP [6].
  • July 2021: finished renovations, adding "multiple cGMP suites" up to 3,000L and "vial-to-vial" production [6].
  • Today: runs 50L, 500L and 3,000L GMP trains, in-house upstream and downstream process development, analytics and QC, and automated fill-finish. It reports more than 100 engineering and GMP batches at 50L or larger since 2019 [5].
  • June 2026: chosen as one of seven participants in the FDA's PreCheck pilot for a new commercial-scale facility in RTP [7].
  • Not disclosed: the CDMO or CRO names, and the square footage of the new plant.
• Investors are paying for manufacturing. The Series D co-lead pointed to manufacturing constraints as what has held gene therapy back [3]. Among 2018–2022 non-AI biotechs, Kriya is the clearest case of a company that builds GMP capacity instead of renting it.
• Headline totals overstate the cash. SEC Form D filings sum to about $870M sold. Aggregators show $927.6M because they count the full announced $150M 2023 extension, and some outlets cite "over $1.2B" [1][4].

5. Financials / Funding

All amounts below are from SEC Form D filings except where noted [1].

• Cumulative: about $870M sold per SEC filings, or about $930M on the headline basis.
• Status: private, with no IPO filing as of October 2026.

6. People & Relationships

• Co-founder and CEO: Shankar Ramaswamy (ex-CBO, Axovant Gene Therapies) [2].
• Vice chair: Roger Jeffs (ex-CEO, United Therapeutics) [1].
• CMO: Greg Di Russo (since December 2025). CFO: Sachiyo Minegishi (since January 2026) [2].
• Investors: Patient Square Capital, Premji Invest, Foresite, and others [1][3].
• Cohort peers in cell and gene therapy: lyell-immunopharma, sana-biotechnology.

Sources

• [1] Kriya Therapeutics, SEC Form D and D/A filings, 2020–2025 (accessed 2026-10-14)
• [2] Research notes on US non-AI drug developers founded 2018–2022, 2026-10-14
• [3] Kriya Series D press release, via BioSpace, 2025-09-10 (accessed 2026-10-14)
• [4] BioPharma Dive, "Kriya adds $150M in fresh funds", July 2023 (accessed 2026-10-14)
• [5] Kriya Therapeutics, manufacturing web page (accessed 2026-10-14)
• [6] Kriya facility renovation press release, BusinessWire, 2021-07-28 (accessed 2026-10-14)
• [7] NCBiotech, "FDA selects 3 NC sites for pilot program", June 2026 (accessed 2026-10-14)